On Dec. 17, 2019, the University of Alabama at Birmingham Comprehensive Cancer Center (UAB) announced that Gregory Friedman, M.D., had been awarded a three-year, $750,000 R01 grant from the U.S. Food and Drug Administration (FDA) for a Phase 1 immunotherapy clinical trial of engineered cold-sore (herpes) virus G207 for the treatment of malignant cerebellar brain tumors in children..